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Novel report of expression and function of CD97 in
malignant gliomas: correlation with Wilms tumor 1
expression and glioma cell invasiveness
Laboratory investigation
Archana Chidambaram, Ph.D.,1 Helen L. Fillmore, Ph.D., 2,3
Timothy E. Van Meter, Ph.D.,1,2 Catherine I. Dumur, Ph.D., 4
and William C. Broaddus, M.D., Ph.D.1,2
Departments of 1Anatomy and Neurobiology, 4Pathology, and 2Neurosurgery/Harold F. Young Neurosurgical
Center, Virginia Commonwealth University, Medical College of Virginia Campus, Richmond; and 3Office of
Research, Old Dominion University, Norfolk, Virginia
Object. The Wilms tumor 1 (WT1) protein—a developmentally regulated transcription factor—is aberrantly
expressed in gliomas and promotes their malignant phenotype. However, little is known about the molecular allies
that help it mediate its oncogenic functions in glioma cells.
Methods. The authors used short interfering RNA (siRNA) to suppress WT1 expression in glioblastoma (GBM)
cells and evaluated the effect of this on GBM cell invasiveness. Gene expression analysis was then used to identify
the candidate genes that were altered as a result of WT1 silencing. One candidate target, CD97, was then selected for
further investigation into its role by suppressing its expression using siRNA silencing, followed by proliferation and
invasion assays.
Results. WT1 levels were reliably and reproducibly suppressed by siRNA application. This resulted in a significant decrease in cellular invasiveness. Microarray analyses identified the gene products that were consistently
downregulated (27) and upregulated (11) with WT1 silencing. Of these, CD97 expression was consistently suppressed across the 3 different GBM cell lines studied and was found on further investigation to significantly impact
GBM cell invasiveness.
Conclusions. Although CD97 expression in gliomas has not been described previously, we conclude that the
possible upregulation of CD97 mediated by WT1 promotes cellular invasiveness—one of the most characteristic
and challenging aspects of glial tumor cells. Further studies are needed to clarify the nature of this regulation and its
impact, as CD97 could represent a novel target for antiglioma therapies.
(http://thejns.org/doi/abs/10.3171/2011.11.JNS111455)
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WT1 protein was originally believed to function as a tumor suppressor. Early studies showed
that the protein repressed the transcription of several oncogenic proteins, such as PDGF-A, transforming
growth factor–b, EGF receptor, and insulin-like growth
factor–I receptor, and increased the expression of genes
that prevented malignant transformation, such as E-cadherin, and proapoptotic proteins (reviewed by Yang et
al.46). However, subsequent studies showed that the ability of WT1 to transcriptionally activate or repress a putative target depended largely on which cell type was being
he

Abbreviations used in this paper: ATP = adenosine triphosphate;
EGF = epidermal growth factor; GBM = glioblastoma; PDGF =
platelet-derived growth factor; qRT-PCR = quantitative reverse transcriptase polymerase chain reaction; SDS = sodium dodecyl sulfate;
siRNA = short interfering RNA; VCU = Virginia Commonwealth
University; WT1 = Wilms tumor 1.
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used, the isoforms studied, the number of WT1 binding
sites present on the target promoter, and other factors (reviewed by Yang et al.46). Moreover, the escalating incidence of its discovery in malignant cells from several different tissue types (reviewed by Sugiyama37) implicated
WT1 in oncogenesis. A key regulator of various developmental processes, WT1 expression was known to be
switched off as tissues developed into the normal adult
stage.15,16,19,35 However, wildtype WT1 was found to be
expressed in leukemias and other hematopoietic malignancies, lung and breast cancers, gastrointestinal cancers,
sarcomas, tumors in the head and neck, reproductive organ neoplasms, and gliomas (reviewed by Sugiyama37).
In most or all of these tumors, WT1 expression appeared
to play a decisive role in promoting proliferation, invasion, and/or angiogenesis.3,6,7,10,11,18,22,24–31,34,36,38,39,42
We have previously demonstrated WT1 expression in
approximately 80% of glioma cell lines and tumor speci843
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mens.5 The predominant WT1 isoform expressed in these
cells contained a 17–amino acid peptide coded for by
exon 5 and the tripeptide KTS between zinc fingers 3 and
4 (WT1 +/+). Our studies showed that glioma cells that
had endogenous WT1 expression relied heavily on this
protein for their growth and motility.3,6 WT1 also conferred upon these cells resistance to radiation therapy and
some chemotherapeutic agents.3,4
In the current study, we examined 2 additional GBM
cell lines—U1242-MG and GBM-6—for the expression
and function of WT1. Previous studies have shown that
these 2 cell lines are highly invasive and mimic the pathology of GBM when implanted orthotopically in athymic mice.12,49 Endogenous expression of WT1 was noted in both these cell lines. We also observed that WT1
profoundly influenced cellular invasiveness in these cell
lines.
The question that arose from these observations then
was: how was WT1 mediating these effects in glial neoplasms?
Given its structural identity—a zinc finger transcription factor—and its functional history, it seemed logical
that WT1 might regulate the transcription (or posttranscriptional expression) of other genes that might then directly cause the above-mentioned effects. Therefore, to
identify which genes might vary in glioma cells in their
expression patterns as a result of WT1-mediated regulation, we used gene microarray analysis to characterize
differential gene expression. This method permits rapid
screening of thousands of genes to find the possible candidate genes that are differentially expressed as a result
of any manipulations. Our analyses revealed the identity
of some such presumed or established oncogenes whose
levels paralleled that of WT1 in glioma cells—PDGF-D,
TYMS, INPP5A, CD97, and FAM57A. Genes whose expression levels were increased as a result of WT1 suppression, on the other hand, included putative tumor suppressors, such as LZTS1, TIMP3, MAFF, and WIPI1. We then
sought to ascertain if there was any correlation between
the expression levels of WT1 and these candidate target
genes in the U1242-MG and GBM-6 cells.
Our experiments showed that CD97 was significantly
downregulated in all 3 cell lines investigated—U251-MG,
U1242-MG, and GBM-6. We selected CD97 for further
investigation, based on its consistent and direct correlation with WT1 across the GBM cell lines examined and
because of its putative roles in facilitating cell invasiveness and neoangiogenesis in gastrointestinal and thyroid
tumors.1,14,21,41,43 This is the first time that expression of
this oncogene has been reported in neoplastic glial cells.
CD97 is a cell surface receptor that belongs to the
adhesion G-protein–coupled receptor (GPCR) family. It
is therefore characterized by heptahelical hydrophobic
segments that form the 7 transmembrane domains, an
extracellular N terminus containing EGF-like structural
domains (comprising the a-subunit), and an intracellular
C terminus.47 Through alternative splicing of the mRNA
transcript, 3 isoforms of the a-subunit of CD97 can be
generated that differ in the number of EGF repeats they
contain; these isoforms are hCD97 (EGF 1, 2, 5), hCD97
(EGF 1, 2, 3, 5), and hCD97 (EGF 1, 2, 3, 4, 5).13 Also
present in the amino-acid sequence of the extracellular
844

segment, after the EGF-like repeats and before the first
membrane-spanning sequence at position 318, is an RGD
motif. This motif acts as a binding site for several classes
of integrins, which are known to mediate attachment to
the extracellular matrix and to other cells.13 The ligands
that have been found to bind CD97 include CD55/decay
accelerating factor (DAF) (involved in protection from
complement-mediated attack and lysis), chondroitin sulfate (a glycosaminoglycan that affects cell attachment),
and a5β1 integrin.41 Interestingly, the intracellular signaling mechanism(s) by which CD97 and other adhesionGPCR family members might act is (are) yet unclear.20
Expression of CD97 has been reported mainly in
leukocytes, and in this group, it has been found predominantly in myeloid cells. CD97 expression has also
been reported in smooth muscle cells and in epithelial
tumors.41 Its expression in thyroid carcinoma cells has
been linked with promoting de-differentiation,1 while
in colorectal and gastric carcinomas and fibrosarcomas,
its expression has been associated with cellular invasiveness.20 Our results corroborated the findings from these
earlier studies and we confirm that in glioma cells, also,
CD97 appears to influence cellular invasiveness. Future
studies will seek to confirm whether WT1 regulates expression of this protein at the transcriptional and/or posttranscriptional level(s).

Cell Culture

Methods

Cells from the human glioma cell line U251-MG
were obtained from ATCC; U1242-MG cells were a kind
gift from Dr. James Van Brocklyn (Ohio State University), and GBM-6 cells were generously provided by Dr. C.
David James (University of California, San Francisco) via
Dr. Paul Dent (VCU). All cells were cultured in DMEM
containing 10% fetal bovine serum, glutamine, nonessential amino acids, and 1% penicillin-streptomycin in a
humidified atmosphere of 5% CO2. Normal human astrocyte RNA (catalog #1805) was procured from ScienCell
Research Laboratories.
Short Interfering RNA Transfections

Cells were plated in 6-well plates at a density of 1.5–
2 × 105 cells per well. Twenty-four hours after plating, the
cells were transfected as described previously.4 Cells were
divided into the following groups: those that had only Oligofectamine (Invitrogen) added to them (ctrl), those that
were treated with nontargeting siRNA control (scr), and
those that had been treated with siRNA targeting WT1 or
CD97 (si). The final concentration of nontargeting siRNA
control, anti-WT1 siRNA, and anti-CD97 siRNA was 100
nM, a concentration that was determined by performing
optimization experiments. Twenty-four hours after transfection, 10% DMEM supplemented with 1% penicillinstreptomycin was added. Forty-eight hours after transfection, the cells were harvested with trypsin, and following
resuspension of the cell pellet in 10% DMEM, the cells
were replated for RNA extraction for qRT-PCR and microarray analyses, protein extraction for Western blotting,
and cell proliferation and/or invasion assays.
J Neurosurg / Volume 116 / April 2012

CD97 and WT1 in malignant gliomas
RNA Extraction

RNA was extracted using Trizol (Invitrogen) according to the manufacturer’s protocol. Following RNA extraction, the RNA content was quantified using a spectrophotometer, and approximately 12 mg of RNA per sample
was subjected to DNase treatment using RQ1 DNase
(Promega). Samples were then analyzed using qRT-PCR.
Synthesis of probes and primers for anti-WT1 siRNA was
carried out at the VCU Nucleic Acid Research Facilities.
The Taqman primer mixes for the target genes were purchased from Applied Biosystems. All qRT-PCR reactions
were performed at the VCU Nucleic Acid Research Facilities.

Western Blotting

Protein was extracted from cell lines using SDS buffer (50 mM Tris-C1, 1% SDS, 10% glycerol) supplemented
with protease inhibitors. The concentration of protein was
determined by DC protein assay (Bio-Rad). For protein
analysis of cells transfected with anti-WT1 siRNA, 10 μg
of total protein lysate was separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose
membrane according to the manufacturer’s protocol (Invitrogen). The membrane was then blocked with 5% nonfat
milk solution for 1 hour at room temperature. Mouse antiWT1 monoclonal antibody (1:200 dilution, clone: 6F-H2,
Dako) and rabbit anti-CD97 polyclonal antibody (1:200,
Abcam) were diluted in blocking buffer, and the blots were
incubated with the respective primary antibodies overnight at 4°C. After this, the membranes were washed 6
times in Tris-buffered saline containing 0.05% Tween-20
before and after a 1-hour incubation at room temperature with horseradish peroxidase–conjugated anti–mouse
(1:2000) and anti–rabbit (1:3000) secondary antibodies directed against anti-WT1 and anti-CD97, respectively. Anticyclophilin A monoclonal antibody (1:30,000, Upstate
Biotechnology) was used as a control for protein loading.
Blots were developed using Pierce SuperSignal West Dura
Substrate.
Cell Proliferation Assay

Cellular proliferation was measured at specified time
points after transfection using the CellTiter-Glo luminescent cell viability assay (Promega). The cells that were
plated in opaque 96-well plates 48 hours after transfection were lysed for 15 minutes in CellTiter-Glo ATP viability assay reagents as per the protocol. Relative luminescence was then detected on a LUMIstar luminescence
plate reader (BMG Labtech).

Invasion Assay

Matrigel (BD Biosciences), previously aliquoted, was
thawed at 4°C on ice overnight before use. Forty-eight
hours posttransfection, cells were plated on Matrigelcoated 8.0-μm pore polycarbonate membrane inserts of
6.5-mm Transwell plates (Corning) at a density of 5000
cells/500 μl. Ninety-six hours following transfection,
the medium was removed from the filters and the lower
chambers, the upper part of each filter was scraped with
cotton-tipped applicators to remove the cells that had not
invaded, and each lower chamber was rinsed with phos-
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phate-buffered saline. Then 200 μl of 1× trypsin-EDTA
(prepared by diluting in phosphate-buffered saline a 10×
solution of 0.5% trypsin-EDTA containing 5 mg/ml of
trypsin with 4.81 mM Na-EDTA in 146.55 mM sodium
chloride) was added to each chamber to harvest the cells,
and after a 5-minute incubation at 37°C, 800 μl of 10%
DMEM was used to neutralize the enzyme. The lower
part of each filter was rinsed with medium to collect cells
that had invaded through the Matrigel-coated insert but
had not adhered to the base of the lower chamber. After
centrifugation at 1000 rpm for 5 minutes to collect the
cells, the supernatant was removed from each tube, and
fresh medium was added to a volume of 500 μl. The entire volume was then plated (100 μl/well) into an opaque
96-well plate for assaying the ATP content as described
above.
Gene Expression Profiling

The microarray reactions were performed using the
Affymetrix GeneChip standard protocol as previously
described.9 Quality analyses of all RNA samples, as well
as cDNA and cRNA synthesis products, were carried out
before proceeding further by running 1 μl of every sample in RNA 6000 Nano or DNA 7500 LabChips on the
2100 Bioanalyzer (Agilent), following the manufacturer’s
protocol. Quality control criteria included cDNA and
cRNA synthesis products within median lengths of 2.0
and 3.0 kb, respectively, and 3ʹ/5ʹ ratios close to 1.00 for
the housekeeping genes, GAPDH and β-actin.8 The “significance-score” algorithm (S-score) developed by Dr. Li
Zhang was used to produce a score for the comparisons
of the expression summaries between cell groups.48 The
Minimum Information About a Microarray Experiment
guidelines have been met, and the microarray raw data
have been deposited with the National Center for Biotechnology Institute Gene Expression Omnibus—accession number GSE22578.
Statistical Analysis

All comparisons were between 2 cell groups: 1) cells
treated with nontargeting siRNA or untreated cells; and
2) cells treated with siRNA directed against WT1 or
CD97. Each experiment was replicated at least 3 times,
and results are presented as mean values with SDs. The
Student t-test (2-tailed, paired) was used, and a calculated
p value of ≤ 0.05 was considered statistically significant.

Results
Expression and Function of WT1 in U1242-MG and
GBM-6 Cells

Using Western blotting, we detected WT1 expression
in U1242-MG and GBM-6 cell lines (Fig. 1A). Cell extracts from the prostatic carcinoma cell line (PC3) were
used as a positive control for WT1. Both GBM-6 and
U1242-MG show the characteristic WT1 double band,
suggesting the possibility of the + and - exon 5 variants
that differ by 17 amino acids, at the predicted molecular
weight level (52–54 kDa).
After using siRNA directed against WT1, we confirmed efficient silencing of this transcription factor by
845
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Fig. 1. Expression and function of WT1 in U1242-MG and GBM-6 cells. A: WT1 expression in GBM-6 and U1242-MG cells
was detected using Western blotting. Twenty micrograms of protein was loaded in each lane. Cell lysates in Lanes A, B, and C
are from PC3 (control), GBM-6, U1242-MG cells, respectively. B: WT1 silencing was confirmed using qRT-PCR (p ≤ 0.001).
WT1 mRNA levels in anti-WT1 siRNA–treated cells are first normalized to the level of the loading control and expressed as a
percentage of the control cells. **p ≤ 0.001. C: WT1 downregulation was associated with a decrease in GBM-6 and U1242-MG
cellular invasiveness at Day 4 posttransfection (*p < 0.05, ***p < 0.001). Cell invasiveness in WT1-silenced cells was assessed
by using the CellTiter-Glo assay (RLU is a surrogate for cell number) to first quantify the number of cells that had invaded through
the Matrigel in the si groups versus the scr groups and then expressing this value as a percentage of that seen in control (scr)
cells. All experiments were performed in triplicate with separate cultured samples of tumor cells treated in parallel with siRNA
against WT1 and corresponding controls.

qRT-PCR (Fig. 1B). On the 3rd day after transfection, we
found that the level of WT1 mRNA in GBM-6 cells treated with anti-WT1 siRNA was 14.44% (± 2.89%) of that
seen in their control counterparts that had been treated
with nontargeting siRNA (p ≤ 0.001). In U1242-MG cells,
there was less knockdown (50.47% [± 3.49%] of control
levels), which was nevertheless highly significant (p ≤
0.001).
We observed that these decreases in cellular content
of WT1 remarkably depressed the invasive capacity of
these cells (Fig. 1C). In GBM-6 cells, there was nearly
a 95% decrease (± 22.65%) in the ability of the anti-WT1
siRNA–treated cells to invade through the Matrigel-coated filter (p ≤ 0.05) compared with the control cells, while
in U1242-MG cells, silencing of WT1 caused a decrease
in cellular invasiveness to 20.62% (± 1.12%) of the control
cells (p ≤ 0.001). These differences in the ability to invade
could potentially be accounted for by decreased proliferative rates in the siRNA-transfected cells versus control
cells. Hence, we performed cell viability assays on these
same groups of cells. Our results showed that the growth
rates of control and siRNA-treated cells were not significantly different across 3 independent experiments (data
not shown). Also, based on our previous experiments we
found no statistically significant differences between untreated cells and cells treated with nontargeting siRNA
(scr). Hence, we show only comparisons between groups
treated with nontargeting and targeting siRNA.
846

Gene Expression Profiling: Putative Target Genes for WT1
in U251-MG Glioma Cells

To ascertain the identity of the potential target genes
for WT1 in the particular context of glioma cells, we
chose to perform gene expression profiling experiments.
On 3 separate occasions, U251-MG cells were treated
with Oligofectamine alone (ctrl), nontargeting RNA (scr),
or siRNA against WT1. After confirming WT1 knockdown with qRT-PCR in the siRNA-treated samples each
time, microarray analyses were carried out using the Affymetrix GeneChip Standard protocol. Quality control
checks were performed, and RNA samples that met the
criteria described in detail in our previous studies40 were
used for microarray analyses. The S-score analyses of the
data obtained in the 3 sets of experiments are summarized in Tables 1 and 2, revealing a total of 27 genes that
were downregulated and 11 genes that were upregulated,
respectively, in response to WT1 silencing. These genes
passed 2 separate levels of stringency for being declared
significantly altered—the S-score, which establishes
significance at the univariate level, and the BenjaminiHochberg correction, which corrects for multiple comparisons.38 The fold change of each gene in these tables
is expressed as the mean value of the results for that gene
from the 3 different microarray experiments. For clarity,
standard deviations for these values are not shown, but
they represented up to 30% of the mean values. SuperJ Neurosurg / Volume 116 / April 2012
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TABLE 1: Gene expression profiling demonstrating the fold
change of genes that are significantly downregulated in
WT1-silenced U251-MG cells*

Gene Title

Gene
Symbol

TABLE 2: Gene expression profiling demonstrating the fold
change of genes that are significantly upregulated in
WT1-silenced U251-MG cells*
Fold Change

Fold Change
si vs ctrl si vs scr

Gene Title

Gene Symbol si vs ctrl si vs scr
CD55

2.46

2.828

0.1649

CD55 molecule, decay accelerating factor for complement (Cromer blood group)

0.25

0.25

spermidine/spermine N1-acetyltransferase 1

SSAT1

2.639

2.639

TYMS

0.26

0.287

WIPI1

2.639

2.828

platelet-derived growth factor-D
LSM14A, SCD6 homolog A (S. cerevisiae)
NADH dehydrogenase (ubiquinone)
1 alpha subcomplex, 1, 7.5 kDa
dihydrolipoamide branched chain
transacylase E2
potassium channel tetramerisation
domain containing 12

PDGF-D
LSM14A

0.26
0.287

0.176
0.26

WD repeat domain, phosphoinositide interacting 1
calcitonin receptor–like

CALCRL

2.639

3.03

LZTS1

2.828

3.73

NDUFA1

0.287

0.287

leucine zipper, putative tumor
suppressor 1

TIMP3

2.828

3.03

DBT

0.33

0.307

KCTD12

0.33

0.33

TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy, pseudoinflammatory)
heme oxygenase (decycling) 1

HMOX1

2.828

2.828

SOX11

2.828

2.46

CD97 molecule
NECAP endocytosis associated 1
BTB (POZ) domain containing 1

CD97
NECAP1
BTBD1

0.33
0.33
0.33

0.307
0.307
0.307

SRY (sex determining region
Y)-box 11

MAFF

3.03

2.828

endothelial PAS domain protein 1
hypothetical protein FLJ10357
secretogranin II (chromogranin C)
mitofusin 1
carboxypeptidase, vitellogenic-like
LSM14A, SCD6 homolog A (S. cerevisiae)
chromosome 14 open reading frame
13
uroporphyrinogen III synthase (congenital erythropoietic porphyria)

EPAS1
FLJ10357
SCG2
MFN2
CPVL
LSM14A

0.353
0.353
0.353
0.353
0.353
0.353

0.287
0.353
0.233
0.33
0.3789
0.33

v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian)
RAR-related orphan receptor B

RORB

3.24

2.828

dihydropyrimidinase-like 3

DPYSL3

3.48

3.73

C14orf135

0.3789

0.3789

UROS

0.3789

0.33

family with sequence similarity
57, member A
serine carboxypeptidase 1
NSFL1 (p97) cofactor (p47)

FAM57A

0.3789

0.353

SCPEP1
NSFL1C

0.3789
0.406

0.33
0.3789

hypothetical protein HSPC111
HSPC111
iron-sulfur cluster assembly 1 homo- ISCA1
log (S. cerevisiae)

0.406
0.406

0.353
0.435

keratin 18
RNA binding motif, single stranded
interacting protein 1

0.406
0.406

0.3789
0.353

intestinal cell (MAK-like) kinase

ICK

0.189

0.287

inositol polyphosphate-5-phosINPP5A
phatase, 40 kDa
chromosome 11 open reading frame C11orf57
57

0.25

thymidylate synthetase

KRT18
RBMS1

* A total of 28 genes were downregulated (including WT1, not shown
in table). Bold type indicates genes that have putative or established
roles in oncogenesis. A total of 3 independent microarray experiments
were conducted.

vised cluster analyses from 3 independent experiments
based on these 38 genes showed that the “ctrl” and “scr”
cell groups cluster together and separately from the “si”
group of cells that were treated with siRNA (Fig. 2). Thus,
Fig. 2 represents an experiment performed in triplicate
J Neurosurg / Volume 116 / April 2012

* A total of 11 genes were upregulated. Bold type indicates genes that
have putative or established roles in suppressing cancers. A total of 3
independent microarray experiments were conducted.

over the course of multiple weeks, with separate cultured
samples of U251-MG cells treated in parallel for knockdown of WT1 expression with corresponding controls.
To the left side of the heat map is a list of all the genes
whose levels were found to be altered with this manipulation. WT1 (highlighted in yellow) appears prominently
downregulated as a result of our experimental treatment,
confirming the successful downregulation using siRNA
knockdown. Also, there is a high level of consistency
in the patterns of up- or downregulation of the selected
genes, among the corresponding replicates (ctrl, scr-, or
si-treated) from the 3 experiments performed.
Among the genes that were downregulated with WT1
silencing, implying a direct correlation, several (identified by searching the available literature) had either putative or established oncogenic roles in gliomas and/or
other malignancies. These genes included ICK, INPP5A,
TYMS, PDGF-D, CD97, EPAS1, FAM57A, KRT18, and
HSPC111 (Table 1). Conversely, the genes that inversely
correlated with WT1 levels included some prominent tumor suppressors such as SSAT1, LZTS1, WIPI1, TIMP3,
SOX11, MAFF, and DPYSL3.
Validation of Microarray Findings Using qRT-PCR

We used qRT-PCR to validate our microarray findings, because it was quicker and more sensitive and would
provide information pertaining to the gene expression lev847
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Fig. 2. Supervised cluster analysis. Two-dimensional hierarchical clustering of samples and genes using Pearson (centered)
correlation and average linkage. Three independent transfection experiments were performed for each microarray analysis.

els, which was of particular interest to us since we were
assessing the potential transcriptional targets of WT1. For
our validation experiments, we selected from among all
the targets identified by microarray only those that had
been implicated as having a relevant role in oncogenesis
or tumor suppression based on literature search. As with
the microarray studies, siRNA-transfection, scr-transfection, and control (Oligofectamine alone) treated cells
were prepared on 3 separate occasions, and RNA extracts
were then subjected to qRT-PCR as described in Methods
for the putative target genes. Furthermore, certain genes
such as ICK, KRT18, and TIMP3 are not represented in
the graph owing to lack of reproducible results. The 2−DDCT
method was used to calculate fold changes in the mRNA
expression levels of the candidate genes against b-actin
mRNA. The values thus obtained for the si groups of cells
were then compared with the corresponding values in the
scr groups of cells. Figure 3 represents a comparison of
the fold change of each candidate gene obtained from the
qRT-PCR analyses (bar graph) against the corresponding
848

value derived from the microarray analyses (line graph).
We successfully substantiated the microarray results with
qRT-PCR by showing that, with both sets of genes, there
is a consistent trend toward down- or upregulation of their
expression levels. In the case of the genes that were downregulated with WT1 silencing, the magnitude of the foldchange values identified by means of qRT-PCR (range
0.25 ± 0.04 to 0.53 ± 0.22) was seen to be close to or only
slightly different from that of the fold-change values obtained through the microarray experiments (0.16–0.35).
With the inversely correlated genes, the fold-change values were much higher in the microarray results (2.6- to
3.7-fold differences) than in the qRT-PCR results (range
0.9 ± 0.21 to 1.9 ± 1.07).
Confirmation of Putative Target Genes in U1242-MG and
GBM-6 Cell Lines

We subsequently investigated whether these genes
that were dysregulated in U251-MG cells were similarly altered by WT1 silencing in U1242-MG and GBM-6
J Neurosurg / Volume 116 / April 2012

CD97 and WT1 in malignant gliomas

Fig. 3. Validation of microarray results. U251-MG cells were transfected with nontargeting siRNA (scr) or WT1-targeting
siRNA (si). RNA samples extracted 48 hours following transfection were analyzed by qRT-PCR. Bar Graph: Fold-change
values of siRNA-treated cells compared with scr controls (depicted by the dashed line at 1) calculated from qRT-PCR experiments. Line Graph: Fold-change values calculated using microarray analyses. Value of scr is set at 1 (depicted by the dashed
line). Transfection was performed on 3 parallel sets of cell cultures to generate these results. *p ≤ 0.05; **p ≤ 0.01.

cells. Both of these cell lines were subjected to siRNA
transfections targeting WT1, and nontargeting siRNA
(scr) was used to generate appropriate controls. Again,
for each cell line, results were generated from 3 independent experiments. Using qRT-PCR, we found that from
among the genes whose expression levels paralleled those
of WT1, INPP5A, CD97, and TYMS were downregulated in the si groups in both U1242-MG and GBM-6
cells compared with scr groups (Fig. 4). In GBM-6 cells,
the extent of knockdown of these genes was as follows:
INPP5A—51.77% ± 0.26% (p ≤ 0.05); CD97—49.6% ±
0.14% (p ≤ 0.01); and TYMS—52.4% ± 0.16%, (p ≤ 0.01).
Additionally, in GBM-6 cells, the expression levels of
PDGF-D and FAM57A in the siRNA-treated groups of
cells were significantly decreased to 16.2% (± 0.06%; p
≤ 0.01) and 44.1% (± 0.23%; p ≤ 0.05) of their scr counterparts, respectively. In U1242-MG cells, the extent of
knockdown of these candidate target genes (as a percentage of scr control) was as follows: INPP5A—65.5%
± 0.11% (p ≤ 0.01); CD97—30.6% ± 0.09% (p ≤ 0.05);
and TYMS—47.7% ± 0.04% (p ≤ 0.01). Additionally, in
U1242-MG cells the expression of EPAS1, a potent angiogenesis facilitator, was also decreased with WT1 silencing. The siRNA-treated U1242-MG cells had 77.5%
of EPAS1 expression compared with their corresponding
control values, although statistical significance could not
be established. For the genes that microarray analyses
J Neurosurg / Volume 116 / April 2012

demonstrated to be upregulated with WT1 silencing (that
is, inversely correlated with WT1 expression), we found a
trend toward an increase in DPYSL and MAFF (GBM-6)
and WIPI1 (U1242-MG), but the high variability across
the 3 independent experiments precluded the establishment of statistical significance.
Analysis of Expression and Function of CD97 in GBM
Cells

Based on our microarray findings and our confirmatory findings using qRT-PCR, we conducted promoter
analyses to look for potential binding sites in the promoter regions of the genes that appeared to be differentially
regulated by WT1 (data not shown). With the exception of
PDGF-D (which had binding sites for Egr-1, but not specifically WT1), all the remaining candidate target genes
were found to have at least 1 potential WT1 binding site
in their promoter regions. This information, coupled with
the consistent CD97 downregulation in all 3 GBM cell
lines that had been treated with anti-WT1 siRNA, led us
to further examine the role of CD97 in these cells with
respect to its expression levels and consequent effects on
cellular invasiveness.
We first determined the expression of CD97 at the
protein level using Western blot analysis, which revealed
that it was expressed in all 3 cell lines examined (Fig.
5A). We then compared the mRNA expression levels of
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it is clear that the expression of CD97 is functionally significant in glioma cells. We also examined the effects on
cellular proliferation (if any) of knocking down CD97,
even though such a role has not frequently been attributed
to this molecule. Our findings showed that there were no
significant differences between the proliferative rates of
the control versus experimental groups across all the 3
cell lines (data not shown).

Discussion

Fig. 4. Confirmation of altered regulation of target genes across different glioma cell lines transfected with anti-WT1 siRNA. Experiments
were performed in triplicate for both GBM-6 and U1242-MG cells. The
x-axes represent the target genes and the y-axes the fold change in si
cells (value of scr set at 1, dashed line). *p ≤ 0.05; **p < 0.01. §§Genes
that were not found to correlate/be expressed.

CD97 in normal human astrocytes to those in the GBM
cell lines—U251-MG, U1242-MG, and GBM-6—and
found 6- to 21-fold greater CD97 mRNA levels in the 3
cell lines than in normal human astrocytes (Fig. 5B).
Subsequently, CD97 expression in all 3 glioma cell
lines was downregulated by siRNA transfection methods,
and the biological effects of this manipulation were examined. As shown in Fig. 5C, qRT-PCR analyses demonstrated a significant knockdown in all 3 cell lines even
at Day 4 posttransfection (p < 0.05). In U251-MG cells,
there was a nearly 50% decrease in CD97 mRNA levels
at this time point, whereas in GBM-6, there was a nearly
80% decrease. In U1242-MG cells, there was a less remarkable knockdown (20% decrease compared with the
control cells), which was nevertheless statistically significant. When plated on Matrigel-coated filters of Transwell
plates, we found that these decreases in CD97 mRNA
levels were associated with significantly lower cellular invasiveness capacities (Fig. 5D). In U251-MG cells treated
with siRNA against CD97, the cellular invasiveness potential was decreased to roughly 53.85% of that of the
control counterparts. In U1242-MG cells, even a modest
decrease in CD97 RNA levels was associated with a striking decrease in invasiveness (25.5% of control), whereas
in GBM-6 cells, the 80% decrease in CD97 mRNA levels
caused a nearly 50% decrease in invasive capacity. Thus,
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We have identified, using gene expression profiling,
genes whose expression levels correlate directly or inversely with WT1 levels in the specific context of malignant gliomas. Of the 27 genes whose expression patterns were positively correlated with that of WT1 (that is,
downregulated with suppression of WT1 expression), 9
candidates were selected for having established or putative oncogenic functions, based on published literature.
Conversely, of the 11 genes whose levels were inversely correlated (upregulated with WT1 silencing), 7 have
been implicated in the suppression of tumorigenesis. We
have validated the microarray findings for these genes in
U251-MG cells with qRT-PCR and have also confirmed
these expression patterns in 2 other GBM cell lines. Our
promoter studies revealed potential binding sites for WT1
in the promoter regions of all but one of the putative target genes. In the lone exception—PDGF-D—the promoter region did, however, show potential binding sites
for the Egr-1 family of transcription factors. It has been
established in previous studies23,35,45 that WT1 shares the
consensus binding sequences recognized and bound by
the Egr-1 family of proteins.
CD97 was uniformly downregulated in all 3 cell
lines with WT1 silencing and displayed sites on its promoter that could be theoretically bound by WT1. Moreover, CD97 is well established as a facilitator of tumor
cell invasiveness in other malignancies. Given these
considerations, we further examined the role of this protein in gliomas. This novel undertaking revealed that in
glioma cells, as in gastrointestinal malignancies and the
fibrosarcoma cell line HT-1080,20 the CD97 receptor fosters cellular invasiveness, and decreasing its endogenous
expression caused a significant and striking decrease in
the ability of the cells to invade through Matrigel.
The complexity of the WT1 protein has long posed a
formidable challenge to those who have ventured to study
its varied functions. Because of its vastly differing roles
in different cell types, categorizing this protein as a tumor suppressor or an oncoprotein is difficult. In certain
cells like the progenitor cells of the kidney, WT1 facilitates their exit from the cell cycle with subsequent differentiation.15 In the neural and vascular progenitor cells,
however, it has the exact opposite effect—facilitating
proliferation and preventing differentiation.15 Hence, any
conclusions about its role(s) must be made strictly in the
context of the cell type examined. We selected the microarray technique to study differences in gene expression
arising out of manipulating the levels of WT1 in glioma
cells that expressed it endogenously. Moreover, silencing
the endogenous expression of the protein to look for the
resultant differences was a more appropriate model to acJ Neurosurg / Volume 116 / April 2012

CD97 and WT1 in malignant gliomas

Fig. 5. Expression and function of CD97 in GBM cells. A: Western blot showing CD97 protein expression (≈ 92 kDa) in
U251-MG, U1242-MG, and GBM-6 glioma cells. Ten micrograms of protein was loaded in each lane. Rabbit polyclonal Ab (Abcam) was used to detect CD97 (1:200). B: Quantitative RT-PCR demonstrated minimal expression of CD97 in normal human
astrocytes (NHA) and a 6- to 21-fold increase in expression in the GBM cell lines investigated. C: Using siRNA directed against
CD97, we confirmed a significant knockdown in CD97 RNA in the tumor cells on Day 4 posttransfection by qRT-PCR in U251-MG,
U1242-MG, and GBM-6 cells. D: Treatment of U251-MG, U1242-MG, and GBM-6 cells with siRNA against CD97 resulted in a
significant decrease in their ability to invade through the Matrigel-coated filters of transwell plates compared with cells that were
treated with nontargeting siRNA. Cell invasiveness in CD97-silenced cells was expressed by using the CellTiter-Glo assay to first
quantify the number of cells that had invaded through the Matrigel in the si groups versus scr groups and then expressing this
value as a percentage of that seen in control (scr) cells. Three independent cultures of U251-MG, GBM-6, and U1242-MG cells
were transfected with corresponding controls. *p < 0.05.

curately assess the possible functions of WT1 rather than
overexpressing WT1 in a WT1 null cell line, due to the
myriad variables (WT1 isoforms and concentration) associated with the latter technique.
Identifying the target genes via which WT1 might
influence its role in the neoplastic transformation of glial
cells was important for many reasons. First, as a regulator
of transcriptional and posttranscriptional processes, WT1
has the ability to coordinate many of the key aspects of
glioma biology—proliferation, invasiveness, and angiogenesis—by regulating the expression of the molecules
that mediate these processes. Moreover, given the rapid
progress that is being made in the field of immunologically targeting WT1,2,17,32,33 our findings help to fill in the
missing links in understanding how it functions. Finally,
knowing the identity of its molecular associates can help
in devising therapeutic strategies that target one or more
of these components. Since these components may belong
to different intracellular signaling pathways, targeting
them simultaneously could work synergistically to have
even greater effects against malignant gliomas.
The identification of at least 9 candidate oncogenes
that were suppressed and 7 putative tumor suppressors
that were upregulated by WT1 silencing confirmed our
hypothesis that in gliomas, WT1 has more of an oncogenic function. Our study has also revealed for the first
time that CD97 is aberrantly overexpressed in GBM
J Neurosurg / Volume 116 / April 2012

cells. This protein has well-documented roles in mediating tumor cell invasion and even angiogenesis1,43 in other
malignant cell types. In various gastrointestinal malignancies, an increased expression of CD97 has been demonstrated at the invading front of the tumor.14,21 Likewise,
we have shown here that in glial neoplastic cells, also,
it has a significant role in conferring invasiveness upon
the cells. From our findings, it appears that in U1242-MG
cells, the extent to which WT1 decreases cellular invasiveness roughly equals that seen with silencing of CD97
expression. In U251-MG and GBM-6 cells, on the other
hand, WT1 silencing causes a much more pronounced decrease in cellular invasiveness than that seen with CD97
silencing alone. In both of these cell lines, expression of
PDGF-D was also seen to be significantly decreased with
lowered expression of WT1. It is well established that
PDGF-D is a strong mitogenic and chemoattractant molecule that can initiate several malignant features, such as
proliferation, invasion, and angiogenesis in brain tumors
(reviewed by Wang et al.44). A more detailed examination
of the relationship of this growth factor to WT1 undoubtedly merits further attention.
We restricted the scope of this study to examining
the expression and function of CD97 in glioma cell lines
to establish well-characterized in vitro model systems
that will allow continuing investigation of the molecular
mechanisms involved with WT1 overexpression and the
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correlated CD97 expression. Further, we chose to compare CD97 expression in these cells to that in normal human astrocytes as there was very little data describing
expression of this proinvasive receptor molecule in the
normal brain tissue components. Clearly, evaluation of
CD97 expression in vivo, both in animal models and in
human tumor samples, will also be needed. Along these
lines, we can confirm that preliminary data from studies
conducted by our laboratory have revealed CD97 mRNA
expression by a high proportion of individual human
glioma samples (data not shown). The detection of significantly higher levels of CD97 in the GBM cell lines
and tumor specimens than is found in normal brain glia
argues for a pathogenic role for this protein. Our results
lay the groundwork for further analyses of the functional
significance of CD97 using more sophisticated experimental techniques, such as brain slice invasion assays or
in vivo studies.
We chose to downregulate CD97 expression as a
more appropriate method in the initial evaluation of its
inherent functional role. Future studies will seek to first
identify the exact isoform(s) of CD97 (containing 3, 4,
or 5 EGF repeats) that is (are) expressed in glioma cells.
Upregulation of the identified isoform(s) in these cells can
then be performed to confirm an increase in cellular invasiveness. Finally, although our promoter studies suggest
putative binding sites for WT1 on the CD97 promoter,
definitive evidence is still required to demonstrate WT1mediated transactivation of CD97 expression.
The ability to localize and therapeutically target the
invading neoplastic cells in situ has for a long time been
a challenge in the treatment of brain tumors. With the
identification of CD97 expression and function in glioma
cells, determining its ability to serve as a reliable marker
of invasiveness using immunohistochemical staining of
glioma tumor specimens opens up a potentially interesting line of investigation. Another option may be to devise
a therapeutic strategy aimed at targeting the CD97 receptor, which could be relatively safe, since it is virtually
absent in normal human astrocytes and the glia of normal
brain (data not shown). Further investigations are also
necessary to determine the effect of targeting the CD97
receptor on angiogenesis, as it is also known to affect this
process.

Conclusions

Our studies emphasize the importance of WT1 in
promoting GBM cellular invasiveness and reveal the
identities of its putative target genes in glioma cells. We
also show, for the first time in glioma cells, the expression
and proinvasive function of CD97. Our study thus opens
important new avenues in the field of glioma biology.
More in-depth analyses of these molecules should carry
us further in our attempts to find novel and more effective
therapeutic targets for the treatment of GBM.
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